Evidence map›Paper›PMID 33601382›Full record

ArticleAmerican journal of nephrology2021

Impact of Circulating N-Acylethanolamine Levels with Clinical and Laboratory End Points in Hemodialysis Patients.

Alex Y Pai, Cachet Wenziger, Elani Streja, Donovan A Argueta, Nicholas V DiPatrizio, Connie M Rhee, Nosratola D Vaziri, Kamyar Kalantar-Zadeh, Daniele Piomelli, Hamid Moradi

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of nephrology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Alex Y PaiDivision of Nephrology, Hypertension and Kidney Transplantation, University of California Irvine School of Medicine, Irvine, California, USA.
Cachet WenzigerDivision of Nephrology, Hypertension and Kidney Transplantation, University of California Irvine School of Medicine, Irvine, California, USA.
Elani StrejaDivision of Nephrology, Hypertension and Kidney Transplantation, University of California Irvine School of Medicine, Irvine, California, USA.
Donovan A ArguetaDivision of Biomedical Sciences, University of California Riverside School of Medicine, Riverside, California, USA.
Nicholas V DiPatrizioDivision of Biomedical Sciences, University of California Riverside School of Medicine, Riverside, California, USA.
Connie M RheeDivision of Nephrology, Hypertension and Kidney Transplantation, University of California Irvine School of Medicine, Irvine, California, USA.
Nosratola D VaziriDivision of Nephrology, Hypertension and Kidney Transplantation, University of California Irvine School of Medicine, Irvine, California, USA.
Kamyar Kalantar-ZadehDivision of Nephrology, Hypertension and Kidney Transplantation, University of California Irvine School of Medicine, Irvine, California, USA.
Daniele PiomelliAnatomy and Neurobiology, University of California Irvine School of Medicine, Irvine, California, USA.
Hamid MoradiDivision of Nephrology, Hypertension and Kidney Transplantation, University of California Irvine School of Medicine, Irvine, California, USA, hamid.moradi@va.gov.
University of California, Irvine · USUniversity of California, Riverside · US

Funding

University of California Health Participation in the National COVID Cohort Collaborative (N3C)UL1TR001414 · NCATS · UNIVERSITY OF CALIFORNIA-IRVINE · PI COOPER, DAN M, VILAIN, ERIC J. · 2015 to 2023
$35.1M
A Randomized Controlled Trial of Thyroid Hormone Supplementation in Hemodialysis PatientsR01DK122767 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI RHEE, CONNIE MEEYOUNG · 2019 to 2023
$3.3M
MALNUTRITION, DIET AND RACIAL DISPARITIES IN CKDK24DK091419 · NIDDK · UNIVERSITY OF CALIFORNIA-IRVINE · PI KALANTAR-ZADEH, KAMYAR · 2011 to 2020
$1.8M
Gut-brain endocannabinoid signaling in feeding behavior and obesityR01DK119498 · NIDDK · UNIVERSITY OF CALIFORNIA RIVERSIDE · PI DIPATRIZIO, NICHOLAS VINCENT · 2019 to 2023
$1.7M
Examining Racial and Cardiovascular Paradoxes in Chronic Kidney DiseaseR01DK078106 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KALANTAR-ZADEH, KAMYAR · 2007 to 2011
$1.1M
A Pilot Feasibility Trial of Thyroid Hormone Replacement in Dialysis PatientsR03DK114642 · NIDDK · UNIVERSITY OF CALIFORNIA-IRVINE · PI RHEE, CONNIE MEEYOUNG · 2017 to 2018
$155k
HDL function and mortality in end stage renal diseaseIK2CX001043 · VA · VETERANS HEALTH ADMINISTRATION · PI MORADI, HAMID · 2015 to 2020
–
Lipid Profiles and Management in Veterans with Chronic Kidney DiseaseIK2CX001266 · VA · VETERANS HEALTH ADMINISTRATION · PI STREJA, ELANI · 2016 to 2021
–
CSRD VA IK2 CX001043CSRD VA IK2 CX001266NCATS NIH HHS UL1 TR001414NIDDK NIH HHS K24 DK091419NIDDK NIH HHS L30 DK114978NIDDK NIH HHS R01 DK078106NIDDK NIH HHS R01 DK119498NIDDK NIH HHS R01 DK122767NIDDK NIH HHS R03 DK114642
6 · The paper itself

Abstract

backgroundPatients with ESRD on maintenance hemodialysis (MHD) are particularly susceptible to dysregulation of energy metabolism, which may manifest as protein energy wasting and cachexia. In recent years, the endocannabinoid system has been shown to play an important role in energy metabolism with potential relevance in ESRD. N-acylethanolamines are a class of fatty acid amides which include the major endocannabinoid ligand, anandamide, and the endogenous peroxisome proliferator-activated receptor-α agonists, oleoylethanolamide (OEA) and palmitoylethanolamide (PEA).

methodsSerum concentrations of OEA and PEA were measured in MHD patients and their correlations with various clinical/laboratory indices were examined. Secondarily, we evaluated the association of circulating PEA and OEA levels with 12-month all-cause mortality.

resultsBoth serum OEA and PEA levels positively correlated with high-density lipoprotein-cholesterol levels and negatively correlated with body fat and body anthropometric measures. Serum OEA levels correlated positively with serum interleukin-6 (IL-6) (rho = 0.19; p = 0.004). Serum PEA and IL-6 showed a similar but nonsignificant trend (rho = 0.12; p = 0.07). Restricted cubic spline analyses showed that increasing serum OEA and PEA both trended toward higher mortality risk, and these associations were statistically significant for PEA (PEA ≥4.7 pmol/mL; reference: PEA <4.7 pmol/mL) after adjustments in a Cox model (hazard ratio 2.99; 95% confidence interval 1.04, 8.64).

conclusionsIn MHD patients, OEA and PEA are significantly correlated with variables related to lipid metabolism and body mass. Additionally, higher serum levels of PEA are associated with mortality risk. Future studies are needed to examine the potential mechanisms responsible for these findings and their clinical implications.

Indexed as

Renal DialysisAdultAgedAmidesEndocannabinoidsEthanolaminesFemaleHumansKidney Failure, ChronicMaleMiddle AgedOleic AcidsPalmitic AcidsAmidesEndocannabinoidsEthanolaminesN-acylethanolaminesOleic AcidsoleoylethanolamidepalmidrolPalmitic AcidsEndocannabinoid systemESRDMaintenance hemodialysisMortalityOleoylethanolamidePalmitoylethanolamide

Identifiers

PMID33601382
PMCPMC7987690
OpenAlexW3132925851

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.